



Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) – Pipeline Review, H1 2018

PUNE, INDIA, April 12, 2018 /EINPresswire.com/ -- WiseGuyReports.com with their unique quality of simplifying the market research study, presents a deep diving study report “Glucose Dependent Insulinotropic Receptor - Pipeline Review, H1 2018”

Glucose Dependent Insulinotropic Receptor

Overview

Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) – G protein-coupled receptor 119 also known as GPR119 is a G protein-coupled receptor that is encoded by the GPR119 gene.

GPR119 is expressed at high concentrations in the pancreas and gastrointestinal tract. GPR119 regulates incretin and insulin hormone secretion. Activation of GPR119 receptor causes a reduction in food intake and weight gain. This target is a potential drug target in treatments for obesity and diabetes.

Click here for sample report @ <https://www.wiseguyreports.com/sample-request/3054163-glucose-dependent-insulinotropic-receptor-g-protein-coupled-receptor>

Major Key Players:

Arena Pharmaceuticals Inc

CymaBay Therapeutics Inc

Dong-A Socio Holdings Co Ltd

GlaxoSmithKline Plc

Glucose Dependent Insulinotropic Receptor Industry Major Outlook

Pharmaceutical and Healthcare latest pipeline guide Glucose Dependent Insulinotropic Receptor - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Glucose Dependent Insulinotropic Receptor , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) targeted therapeutics development with respective active and dormant or discontinued projects.

Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 10 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively

Glucose Dependent Insulinotropic Receptor pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Glucose Dependent Insulinotropic Receptor - Competitive Analysis

Key players are making innovative developments in Glucose Dependent Insulinotropic Receptor industry. The same will help in improving the market performance. Heavy investments are made by major players in the R&D sector

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Glucose Dependent Insulinotropic Receptor.

The pipeline guide reviews pipeline therapeutics for Glucose Dependent Insulinotropic Receptor by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Glucose Dependent Insulinotropic Receptor therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Glucose Dependent Insulinotropic Receptor therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Glucose Dependent Insulinotropic Receptor.

.Continued

For Detailed Reading Please visit @ <https://www.wiseguyreports.com/reports/3054163-glucose-dependent-insulinotropic-receptor-g-protein-coupled-receptor>

About Us

Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.

Contact Us:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

www.wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

Norah Trent

WiseGuy Research Consultants Pvt. Ltd.

+1 646 845 9349 / +44 208 133 9349

[email us here](mailto:sales@wiseguyreports.com)

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2018 IPD Group, Inc. All Right Reserved.